Synvisc Approved In Australia For Osteoarthritis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Synvisc Approved In Australia For Osteoarthritis

RIDGEFIELD, NJ -- Dec. 18, 1998 -- The Australian Therapeutic Goods Administration has approved Biomatrix, Inc.’s Synvisc(R) for the treatment of pain in osteoarthritis of the knee.

The company also announced that it has received approvals to market Synvisc in Malaysia, Singapore and Thailand.

Synvisc is an intra-articular treatment for osteoarthritis of the knee, a painful and debilitating joint disease in which the elastoviscous properties of the synovial fluid in the knee joint diminish, resulting in less protection and shock absorption. It is used for patients who do not get adequate relief from simple painkillers (for example, acetaminophen) or from exercise and physical therapy.

Related Links: Synvisc, Biomatrix, Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities